Welcome to our dedicated page for 180 Life Sciences news (Ticker: ATNF), a resource for investors and traders seeking the latest updates and insights on 180 Life Sciences stock.
180 Life Sciences Corp. Common Stock (symbol: ATNF) represents a pioneering clinical-stage biotechnology company based in Menlo Park, California. The company focuses on developing innovative therapeutics to address unmet medical needs in chronic pain, inflammation, and fibrosis.
The company has several key product development platforms currently in Phase IIb/III clinical trials:
- Fibrosis and Anti-TNF Platform: This platform targets the treatment of fibrosis and anti-tumor necrosis factors, a major cause of inflammation.
- Synthetic Cannabidiol (CBD) Analogs Platform: This platform includes man-made derivatives of CBD designed to offer therapeutic benefits.
- α7nAChR Platform: Focused on the alpha 7 nicotinic acetylcholine receptor, which plays a role in modulating inflammation and pain.
180 Life Sciences Corp. is committed to advancing its drug candidates through robust clinical trials and cutting-edge research. From addressing postoperative pain relief with orally absorbed CBD tablets to combating chronic inflammation and fibrosis, the company's innovative approach highlights its significance in the biotechnology landscape.
The company’s recent achievements include a notable presentation by Dr. Michael J. Alaia at the 2022 American Academy of Orthopaedic Surgeons Annual Meeting. The talk focused on the efficacy of CBD tablets for postoperative pain relief, showcasing the potential impact of 180 Life Sciences Corp.'s therapies.
For more information, investors can contact Jason Assad, Director of Investor Relations, at jassad@180lifesciences.com.
180 Life Sciences Corp. (NASDAQ: ATNF) announced the closing of its registered direct offering, selling 1,570,680 shares of common stock and warrants, generating approximately $3 million in gross proceeds. The shares were priced at $1.91 each, with warrants allowing purchase at $1.78. The net proceeds will fund research and development expenses, including a marketing authorization application.
A.G.P./Alliance Global Partners acted as the placement agent. The offering is based on an effective shelf registration statement with the SEC filed previously. Additionally, existing warrants for 2,878,032 shares will be amended to lower the exercise price to $1.78 and extend the expiration.
180 Life Sciences Corp. (NASDAQ: ATNF) announced a definitive agreement for a registered direct offering to sell 1,570,680 shares of common stock at a price of $1.91 each, alongside warrants to purchase the same amount at an exercise price of $1.78. The total gross proceeds from this offering are expected to be around $3 million, aimed at funding research, development, and corporate expenses. The offering is set to close on or around April 10, 2023. As part of this transaction, existing warrants for 2,878,032 shares will also be amended to lower the exercise price to $1.78 and extend the expiration to five and a half years.
FAQ
What is the current stock price of 180 Life Sciences (ATNF)?
What is the market cap of 180 Life Sciences (ATNF)?
What does 180 Life Sciences Corp. specialize in?
Where is 180 Life Sciences Corp. headquartered?
What are the key platforms of 180 Life Sciences Corp.?
What stage are the company's product development platforms in?
Who can be contacted for investor relations?
What is the focus of the recent talk presented by Dr. Michael J. Alaia?
What is the company's ticker symbol?
What unmet medical needs does 180 Life Sciences Corp. aim to address?
What is the significance of the α7nAChR platform?
How can I stay updated with the latest news about 180 Life Sciences Corp.?
